Skip to main content
Clinical Trials/ISRCTN59862351
ISRCTN59862351CompletedPhase 4

PATCH Trial: Post-tonsillectomy Analgesia with buprenorphine Transdermal patCH: a prospective, randomised, phase IV, open label clinical trial to study the therapeutic use of buprenorphine 20 mg (Transtec®) matrix transdermal patch in the management of post-tonsillectomy pain in adults

orth West Wales NHS Trust (UK)0 sites133 target enrollmentStarted: April 16, 2008Last updated:

Trial Snapshot

Phase
Phase 4
Status
Completed
Sponsor
Enrollment
133

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Sex
All

Inclusion Criteria

  • Patients undergoing tonsillectomy, who meet the following criteria:
  • 1. Aged 18 to 50 years old, either sex
  • 2. American Society of Anaesthesiologists (ASA) grade I and II: healthy patient, mild systemic disease with no functional limitation (e.g., well controlled hypertension [HTA])

Exclusion Criteria

  • 1. Age less than 18 or over 50 years
  • 2. ASA grade III - severe systemic disease with definite functional limitation (e.g., unstable angina)
  • 3. Any condition in which the respiratory centre and function are severely impaired or may become so
  • 4. Asthmatic and allergic to non-steroidal anti-inflammatory drugs (NSAIDS)
  • 5. Hypotension
  • 6. Pregnancy and lactation
  • 7. Recent head injury
  • 8. Known hypersensitivity towards the active substance buprenorphine or to any of the excipients
  • 9. Opioid-dependent patients, or patients in narcotic withdrawal treatment
  • 9. Patients who are receiving monoamine oxidase (MAO) inhibitors or have taken them within the last two weeks
  • 10. Patients suffering from myasthenia gravis
  • 11. Patients suffering from delirium tremens or acute alcohol intoxication
  • 12. Convulsive disorders

Investigators

Sponsor
orth West Wales NHS Trust (UK)

Similar Trials